LYMPHOID NEOPLASMS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION. THE CASE OF SECONDARY HODGKIN’S LYMPHOMA, DIFFERENTIAL DIAGNOSIS WITH POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE

Secondary malignant diseases are dangerous long-term complications of allogeneic hematopoietic stem cell transplantation (HSCT). This article describes the group of secondary lymphoid neoplasms and presents a rare case of secondary Hodgkin disease in a 21-year patient 6 years after HSCT due to acute myeloid leukemia. This complication should be distinguished from the Hodgkin-like posttransplant lymphoproliferative disease, because of the different therapy approaches and outcomes. We describe their main features and differential diagnostic procedures. 

1. Deeg H.J., Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998,91:1833–44. PMID: 9490664.

2. Inamoto Y., Shah N.N., Savani B.N. et al. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant 2015,50(8):1013–23 DOI: 10.1038/bmt.2015.63. PMID: 25822223.

3. Majhail N.S. Old and new cancers after hematopoietic-cell transplantation. Hematology Am Soc Hematol Educ Program 2008:142–9. DOI: 10.1182/asheducation-2008.1.142. PMID: 19074072.

4. Penn I., Hammon W., Brettschneider L. et al. Malignant lymphomas in transplantation patients. Transplant Proc 1969,1:106–12. PMID: 4944206.

5. Cockfield S.M. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001,3(2):70–8. PMID: 1139597247.

6. Baker K.S., DeFor T.E., Burns L.J. et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003,21(7):1352–8. Erratum in: J Clin Oncol 2003,21(16):3181. DOI: 10.1200/JCO.2003.05.108. PMID: 12663726.

7. Orazi A., Hromas R.A., Neiman R.S. et al. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Pathol 1997,107: 419–29. PMID: 9124210.

8. Hoover R.N. Lymphoma risks in populations with altered immunity — a search for mechanism. Cancer Res 1992,52:5477s. PMID: 1394157.

9. Cohen J.I. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) 1991,70:137–60. PMID: 1848644.

10. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998,338:1413–21. DOI: 10.1056/NEJM199805143382003. PMID: 9580648.

11. Nalesnik M.A., Makowka L., Starzl T.E. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988,25:367–72. PMID: 3063441.

12. Leblond V., Davi F., Charlotte F. et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998,16(6):2052–9. PMID: 9626203.

13. Gong J.Z., Bayerl M.G., Sandhaus L.M. et al. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children. Am J Surg Pathol 2006,30(3):328–36. DOI: 10.1097/01.pas.0000188030.63706.e7. PMID: 16538052.

14. Brunstein C.G., Weisdorf D.J., DeFor T. et al. Marked increased risk of EpsteinBarr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006,108(8):2874–80. DOI: 10.1182/blood-2006-03-011791. PMID: 16804113.

15. Snyder M.J., Stenzel T.T., Buckley P.J. et al. Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol 2004,28(6):794–800. PMID: 151666725.

16. Bollard C.M., Rooney C.M., Heslop H.E. T-cell therapy in the treatment of posttransplant lymphoproliferative disease. Nat Rev Clin Oncol 2012,9(9):510–29. Epub 2012 Jul 17. Review. DOI: 10.1038/nrclinonc.2012.111. PMID: 22801669.

17. Rowlings P.A., Curtis R.E., Passweg J.R. et al. Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. J Clin Oncol 1999,17(10):3122–7. PMID: 10506608.

18. GrulichA.E.,VanLeeuwenM.T.,FalsterM.O. et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a metaanalysis. Lancet 2007,370(9581):59–67. Review. DOI: 10.1016/S0140-6736(07)61050-2. PMID: 17617273.

19. Gottschalk S., Rooney C.M., Heslop H.E. Post-transplant lymphoproliferative disorders. Annu Rev Med., 2005,56:29–44. DOI: 10.1146/annurev.med.56.082103.104727. PMID: 15660500.

20. Loren A.W., Porter D.L., Stadtmauer E.A. et al. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003,31(3):145–55. DOI: 10.1038/sj.bmt.1703806. PMID: 12621474.

21. Dierickx D., Tousseyn T., Sagaert X. et al. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma 2013,54(11):2433–40. DOI: 10.3109/10428194.2013.780655. PMID: 23442063.

22. Epstein-Barr virus and lymphoproliferative disorders after transplantation. Am J Transplant 2004,4(Suppl.10):59–65. DOI: 10.1111/j.1600-6135.2004.00728.x. PMID: 15504214.

23. Luskin M.R., Heil D.S., Tan K.S. et al. The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder. Am J Transplant 2015,15(10):2665–73. DOI: 10.1111/ajt.13324. PMID: 25988622.

24. Jaffe E.S., Harris N.L., Stein H. et al. Pathology and genetics of tumours of the haematopoietic and lymphoid tissues. In: World Health Organization Classification of Tumours, vol. 3. Lyon, France: IARC Press, 2001. P. 264–9.

25. Dierickx D., Tousseyn T., Gheysens O. How I treat posttransplant lymphoproliferative disorders. Blood 2015,126(20):2274–83. DOI: 10.1182/blood-2015-05-615872. PMID: 26384356.

26. Semakula B., Rittenbach J.V., Wang J. Hodgkin lymphoma-like posttransplantation lymphoproliferative disorder. Arch Pathol Lab Med 2006,130(4):558–60. DOI: 10.1043/1543-2165(2006)130[558:HLPLD]2.0.CO,2. PMID: 16594752.

27. Pitman S.D., Huang Q., Zuppan C.W. et al. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically. Am J Surg Pathol 2006,30(4):470–6. PMID: 16625093.

28. Rohr J.C., Wagner H.J., Lauten M. et al. Differentiation of EBV-induced posttransplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease. Pediatr Transplant 2008,12(4):426–31. DOI: 10.1111/j.1399-3046.2007.00816.x. PMID: 18466428.

29. Ranganathan S., Webber S., Ahuja S. et al. Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma? Pediatr Dev Pathol 2004,7(4):348–60. DOI: 10.1007/s10024-003-1115-0. PMID: 14564542.

30. Tsao L., Hsi E.D. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 2007,131(8):1209–18. DOI: 10.1043/1543-2165(2007)131[1209:TCSOPL]2.0.CO,2. PMID: 17683183.

31. Krishnamurthy S., Hassan A., Frater J.L. et al. Pathologic and clinical features of Hodgkin lymphoma-like posttransplant lymphoproliferative disease. Int J Surg Pathol 2010,18(4):278–85. Erratum in: Int J Surg Pathol 2010,18(5):444. DOI: 10.1177/1066896909338597. PMID: 19578050.

32. Pitman S.D., Huang Q., Zuppan C.W. et al. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically. Am J Surg Pathol 2006,30(4):470–6. PMID: 16625093.

33. Takehana C.S., Twist C.J., Mosci C. et al. (18)F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder. Nucl Med Commun 2014,35(3):276–81. DOI: 10.1097/MNM.0000000000000050. PMID: 24296883.